Having just raised $125m and presented promising mid-stage data on apraglutide, VectivBio Holding AG is making strides in its bid to become the leading player in the short bowel syndrome (SBS) space currently dominated by Takeda Pharmaceutical Co. Ltd.'s Gattex.
The Swiss biotech, established in May 2019 as a spin-off from Therachon Holding AG following the latter's $810m acquisition...